Summary.-The effects of C. parvum on RFM/UN myeloid leukaemia were studied. Mice inoculated with 7-0 mg but not 0-7 mg C. parvum i.p. survived significantly longer than untreated leukaemic mice (P < 0-001). Administration of silica abrogated the effects of C. parvum, whilst polyvinyl pyridine-N-oxide prevented the inhibitory effects of silica. These studies demonstrate that a single large dose of C. parvum, either before or after leukaemic-cell passage, can significantly prolong the survival of RFM mice bearing myeloid leukaemia. The effects of silica and PVNO on C.
parv'um suggest a critical role for macrophages in C. parvum effects on myeloid leukaemia.
C. Parrvrn is a non-specific stimulator of the immune system which has been shown to exert antitumour activity i both animal (Currie & Bagshawe, 1970; Scott, 1974a; Fisher et al., 1975; Suit et al., 1977; Houchens et al., 1976) and human tumours (Scott, 1 974b; Israel et al., 1975; .
In this communication we report our initial studies of the effects of C. parrurn on murine myeloid leukaemia (Preisler et al., 1977) . The effects of this immune stimulator are dose-dependent and demonstrable by the prolongation of survival of leukaemic mice. The administration of silica prevents the beneficial effects of C. parvum on this leukaemia, whilst polyvinyl pyridine N-oxide (PVNO) abrogates the inhibitory effects of silica.
AIATERIALS AND METHODS
A. Mice and tumour. Inbred RFM/UN female mice were used in these experiments. The mice were bred in our own animal facility. The pathophysiology of this murine leukaemia has been previously described (Preisler et al., 1977) . Mice, were inoculated i.v. with spleen-cell suspensions from terminal leukaemic RFM mice, with the appropriate number of cells suspended in 0-2 ml saline. There were 5 mice in each experimental group, and food and water were allowed ad lib. At death, internal organs wvere inspected and livers and spleens weighed and fixed in formalin for hiistopathological studies. Each experiment was performed at least 3 times.
B. C. parrum -The C. parrurn which wAas kindly furnished by Burroughs 'ellcome Company Research, Triangle Park, N.C., U.S.A., contained 7 mg dry weight of formalin-killed organisms per millilitre, suspended in 0-9o NaCl solution. Within each experiment varying, amounts of C. parvum were always injected by the same route and in the same total volume. C. Silica, polyvinyl pyridine N-oxide (PVNO).-In some experiments mice received either silica (2-5 mg in 1 ml PBS) i.v. on the day of tumour transplantation (i.e. 2 days before inoculation of C. parvum where applicable) and/or P VNO (4 mg in 01 ml PBS) s.c. one day before tumour transplantation. (Table III) .
RESULTS

EJffects
mice was highly significant (P < 0 001, Breslow test).
Histopatholoqical studies
At the time of death, control leukaemic mice and those inoculated with C. parvum had massive hepatosplenomegaly, with diffuse infiltration by leukaemic cells. Leukaemic-cell thrombi of the pulmonary arteries appeared to be the immediate cause of death of both treated and control mice (Fig. 2) . Mice which had been inoculated with C. parruvn differed from control mice in that organ infiltration by leukaemic cells was less. There was evidence of significant tissue necrosis only in the spleens and livers of mice which had been inoculated with C. parvum. The histopathological findings in the mice receiving 0 7 and 7 0 mg C. parvum were indistinguishable at the time of death (Fig. 3) .
Effects of silica and PIYNO on leukacinic mice inoculated with C. parvurun
In 3 of the experiments described in Table II , groups of mice received silica and/or PVNO in addition to or instead of C. parvum. to determine which experimental groups were significanitly different from each other.
The administration of silica, PVNO, or PVNO + silica had no effect on the survival of mice, compared to the control group. By contrast, survival was significantly prolonged in mice which received C. parvum or PVNO + C. parvum. The administration of silica to mice which received C. parvum abrogated the increase in survival produced by C.
parvrum. The administration of PVNO to mice which received silica and C. parvum abrogated the inhibitory effects of silica and restored the beneficial effects of C. parvum. The observation that mice which received C. parvum together with PVNO survived the longest is of interest. (Houchens et al., 1976) , which is the only murine leukaemia in which C. parvum alone has been found to be effective (Houchens et al., 1976; Mathe et al., 1969; Scott, 1974a) . The dose levels of C. parvum in the previously reported studies were much lower than the 250-300 mg/kg levels in our studies. This difference in dose levels may in part explain the apparent lack of effectiveness of C. parvum in the tested systems. Also, L 1210 and AKR leukaemias are lymphoid malignancies, passaged i.p. in the reported experiments, which may for these reasons have responded differently to C. parvrum from our myeloid leukaemia.
C. parvum has been shown to be a general stimulant of the reticuloendothelial system and of macrophages (Woodruff and Dunbar 1973 Lotzova & Cudkowicz (1974) with respect to marrow grafts. These observations, taken together with those now reported, lead to the conclusion that the increased survival of mice with myeloid leukaemia is dependent upon stimulation of intact macrophage function. This has been shown in several other tumour systems (McBride et al., 1975; Keller, 1977; , 1978b) . Histopathologic studies of leukaemic mice treated with C. parvum showed hepatosplenomegaly, with necrotic areas in the liver and spleen, as previously described by Lampert et al. (1977) , possibly caused by intravascular coagulation resulting from antigen-antibody interaction. In preliminary studies we found that the administration of C. parvum to normal mice did not cause death. The terminal event in the leukaemic mice appeared to be leukaemic-cell pulmonary emboli and/or thrombi, the apparent immediate cause of death of mice with this myeloid leukaemia (Preisler et al., 1977) . Hence, despite toxicity related to the administration of C. parvum, the mice ultimately died from leukaemia.
The studies described here suggest that the administration of C. parvum might be of therapeutic benefit for patients with acute myelocytic leukaemia. An initial study of C. parvum in the treatment of leukaemia in man failed to demonstrate any therapeutic benefit (Pavlovsky et al., 1978) . On the basis of our dose-response experience in the mouse studies presented here, one would expect to see therapeutic benefit only with C. parvum doses which are far in excess of any doses hitherto administered to man. Clearly the hepatosplenic toxicity seen at the high doses administered to our mice would seem to make such an attempt unwise. Because of the possible relationship between the presence of C. parvum bacilli in the bloodstream and the toxic manifestations, we are currently attempting to circumvent this problem by encapsulating the bacilli within phospholipid vesicles (Papahadjopoulos and Preisler, unpublished observation). Since i.v. administered phospholipid vesicles are rapidly cleared by the reticuloendothelial system, we will attempt to deliver the encapsulated C. parvum directly to the phagocytic cells of reticuloendothelial system while avoiding direct exposure of other tissues to the bacterium.
